Momenta, Sandoz develop and market complex drugs; expanded in separate deal
Executive Summary
Momenta (sugar sequencing and engineering) will combine its complex sugars technologies with the expertise of Novartis' generic unit Sandoz to jointly develop and market a generic equivalent of injectable enoxaparin--generic of Lovenox-- and potential improved forms of it. The drug is a low-molecular weight heparin for preventing and treating deep vein thrombosis and for treating acute coronary syndromes.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice